Efficacy and Safety

Efficacy and Safety Overview

DUPIXENT demonstrated efficacy and safety across clinical trials

See how DUPIXENT reduced severe exacerbations, improved lung function, reduced or eliminated OCS use, and has demonstrated safety profile.

Adults and Pediatric Patients (12+ Years)

Exacerbations

Reduced severe
exacerbations by up to 81%^1,a

SEE RESULTS

Lung Function

Rapid and sustained
improvement in lung function
through 52 weeks^1,b

SEE RESULTS

OCS Reduction

Only biologic indicated
for OCS-dependent asthma
patients¹

SEE RESULTS

Quality of Life

Resulted in improved asthma
control and quality of life^1,c,d

SEE RESULTS

Safety Data

Demonstrated safety across 3
clinical trials¹

SEE SAFETY DATA

Study Designs

Studied up to 1 year in nearly
3000 asthma patients¹

SEE STUDY DESIGNS

TRAVERSE
Long-term Data

~3-year data across key
measures of asthma control^1,2

SEE RESULTS

^aWith DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood eosinophils ≥300 cells/μL (DRI12544, secondary endpoint).¹

^b470 mL improvement at Week 52 from baseline in pre-bronchodilator FEV₁ with DUPIXENT 200 mg + SOC (n=264) vs 170 mL improvement with placebo + SOC (n=148) (QUEST, EOS ≥300 cells/µL, secondary endpoint). ~72% of the total FEV₁ improvement seen after the first dose at Week 2.¹

^c75% of patients improved ACQ-5 (asthma control) score with DUPIXENT 200 mg + SOC vs 67% with placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35]) (QUEST, secondary endpoint).¹

^d71% of patients improved AQLQ (quality of life) score with DUPIXENT 200 mg + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (QUEST, secondary endpoint).¹